Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Grand Pharmaceutical Group Limited has announced the successful enrollment of the first patient in its innovative clinical trial for GPN00289, a temperature-sensitive embolic agent aimed at treating primary liver cancer. This novel product combines the advantages of liquid and solid embolization to improve the effectiveness of chemoembolization treatments. With a global sales network, the company is poised to strengthen its presence in the nuclear medicine anti-tumor market.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.